Abstract

This paper examines how Artificial Intelligence (AI) has transformed cardiovascular pharmacology. With cardiovascular diseases still one of the leading causes of global morbidity and mortality, AI comes to play a special role in changing the face of an aging world. This paper delves into the different aspects of AI in cardiovascular pharmacology. Among these are its use for predictive modeling, big data integration, and acceleration of drug discovery and patient care processes. We talk about the progress achieved by AI technologies such as machine learning, deep learning and data analytics; how they can enhance diagnostic accuracy, tailor treatment to fit individual patients, and optimize drug development. Moreover, the paper explores the problems and ethical challenges involved in incorporating AI into health care--data privacy; algorithmic bias; lack of transparency. Combining the use of case studies, actual applications and future prospects, it paints a clear picture of how AI will radically change cardiovascular pharmacology. The paper shows that artificial intelligence is already changing patient clinical outcomes today and how healthcare costs for society overall may follow suit in the near future.

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.